Evidence map›Paper›PMID 29032150›Full record

ArticleGene2018

Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases.

Tharani Sundararajan, Ann M Manzardo, Merlin G Butler

Abstract read
In one paragraph

Article in Gene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Autoimmune neuropsychiatric disorders manifesting with psychosis.The Journal of clinical investigation · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. CaFrontiers in cellular neuroscience · 2023
    Article
  16. Article
  17. Article
  18. CaFrontiers in pharmacology · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tharani SundararajanDepartment of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, KS, United States.
Ann M ManzardoDepartment of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, KS, United States.
Merlin G ButlerDepartment of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, KS, United States; Department of Pediatrics, University of Kansas Medical Center, Kansas City, KS, United States. Electronic address: mbutler4@kumc.edu.
University of Kansas Medical Center · US

Funding

Research Design and Analysis Core (RDAC)P30HD002528 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 1985 to 2015
$22.1M
NICHD NIH HHS P30 HD002528
6 · The paper itself

Abstract

Schizophrenia (SCZ) is a chronic debilitating neuropsychiatric disorder with multiple risk factors involving numerous complex genetic influences. We examined and updated a master list of clinically relevant and susceptibility genes associated with SCZ reported in the literature and genomic databases dedicated to gene discovery for characterization of SCZ genes. We used the commercially available GeneAnalytics computer-based gene analysis program and integrated genomic databases to create a molecular profile of the updated list of 608 SCZ genes to model their impact in select categories (tissues and cells, diseases, pathways, biological processes, molecular functions, phenotypes and compounds) using specialized GeneAnalytics algorithms. Genes for schizophrenia were predominantly expressed in the cerebellum, cerebral cortex, medulla oblongata, thalamus and hypothalamus. Psychiatric/behavioral disorders incorporating SCZ genes included ADHD, bipolar disorder, autism spectrum disorder and alcohol dependence as well as cancer, Alzheimer's and Parkinson's disease, sleep disturbances and inflammation. Function based analysis of major biological pathways and mechanisms associated with SCZ genes identified glutaminergic receptors (e.g., GRIA1, GRIN2, GRIK4, GRM5), serotonergic receptors (e.g., HTR2A, HTR2C), GABAergic receptors (e.g., GABRA1, GABRB2), dopaminergic receptors (e.g., DRD1, DRD2), calcium-related channels (e.g., CACNA1H, CACNA1B), solute transporters (e.g., SLC1A1, SLC6A2) and for neurodevelopment (e.g., ADCY1, MEF2C, NOTCH2, SHANK3). Biological mechanisms involving synaptic transmission, regulation of membrane potential and transmembrane ion transport were identified as leading molecular functions associated with SCZ genes. Our approach to interrogate SCZ genes and their interactions at various levels has increased our knowledge and insight into the disease process possibly opening new avenues for therapeutic intervention.

Indexed as

Genome-Wide Association StudyAmino Acid Transport SystemsCalcium ChannelsCerebellumCerebral CortexDatabases, GeneticHumansHypothalamusIon TransportMedulla OblongataMembrane PotentialsReceptors, DopamineReceptors, GABA-AReceptors, Ionotropic GlutamateReceptors, SerotoninSchizophreniaAmino Acid Transport SystemsCalcium ChannelsReceptors, DopamineReceptors, GABA-AReceptors, Ionotropic GlutamateReceptors, SerotoninFunction and biological mechanismGene interactionGenome wide pathway analysisSchizophrenia spectrum

Identifiers

PMID29032150
PMCPMC6706854
OpenAlexW2763205045

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.